Misplaced Pages

:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Tanespimycin: Difference between pages - Misplaced Pages

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Difference between pages)
Page 1
Page 2
Content deleted Content addedVisualWikitext
Revision as of 16:50, 16 February 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{chembox}} taken from revid 459645162 of page 17-N-Allylamino-17-demethoxygeldanamycin for the Chem/Drugbox validation project (updated: 'CASNo').  Latest revision as of 19:43, 24 March 2024 edit Boghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,738 edits consistent citation formatting 
Line 1: Line 1:
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{ambox | text = This page contains a copy of the infobox ({{tl|chembox}}) taken from revid of page ] with values updated to verified values.}}
{{chembox {{chembox
| Verifiedfields = changed | Verifiedfields = changed
| verifiedrevid = 457644489 | verifiedrevid = 477209222
| Name=Tanespimycin
⚫ | Name=17-''N''-Allylamino-17-demethoxygeldanamycin
| ImageFile = 17-N-Allylamino-17-demethoxygeldanamycin.svg | ImageFile = 17-N-Allylamino-17-demethoxygeldanamycin.svg
| ImageSize = | ImageSize = 200px
| IUPACName = docosa-8,12,14,18,21-<br />pentaen-10-yl] carbamate | IUPACName = docosa-8,12,14,18,21-pentaen-10-yl] carbamate
⚫ | OtherNames = 17-''N''-Allylamino-17-demethoxygeldanamycin<br>17-AAG
| OtherNames =
| Section1 = {{Chembox Identifiers |Section1={{Chembox Identifiers
| IUPHAR_ligand = 7751
| InChI = 1/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1 | InChI = 1/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1
| InChIKey = AYUNIORJHRXIBJ-TXHRRWQRBY | InChIKey = AYUNIORJHRXIBJ-TXHRRWQRBY
| SMILES1 = C1C(((/C=C(/((/C=C\C=C(\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)/C)OC)OC(=O)N)\C)C)O)OC | SMILES1 = C1C(((/C=C(/((/C=C\C=C(\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)/C)OC)OC(=O)N)\C)C)O)OC
Line 17: Line 18:
| StdInChIKey = AYUNIORJHRXIBJ-TXHRRWQRSA-N | StdInChIKey = AYUNIORJHRXIBJ-TXHRRWQRSA-N
| CASNo_Ref = {{cascite|changed|??}} | CASNo_Ref = {{cascite|changed|??}}
| CASNo = <!-- blanked - oldvalue: 75747-14-7 --> | CASNo = 75747-14-7
| PubChem = 6440175 | PubChem = 6440175
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 109480 | ChEMBL = 109480
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4GY0AVT3L4
| ChemSpiderID = 21106220 | ChemSpiderID = 21106220
| SMILES = NC(=O)O1C(/C)=C/(C)(O)(OC)C(C)C\C2=C(/NCC=C)C(=O)\C=C(\NC(=O)C(\C)=C\C=C/1OC)C2=O | SMILES = NC(=O)O1C(/C)=C/(C)(O)(OC)C(C)C\C2=C(/NCC=C)C(=O)\C=C(\NC(=O)C(\C)=C\C=C/1OC)C2=O
}} }}
| Section2 = {{Chembox Properties |Section2={{Chembox Properties
| C=31 | H=43 | N=3 | O=8
| Formula = C<sub>31</sub>H<sub>43</sub>N<sub>3</sub>O<sub>8</sub>
| Appearance =
| MolarMass = 585.689 g/mol
| Appearance = | Density =
| Density = | MeltingPt =
| MeltingPt = | BoilingPt =
| BoilingPt = | Solubility =
| Solubility =
}} }}
| Section7 = {{Chembox Hazards |Section7={{Chembox Hazards
| MainHazards = | MainHazards =
| FlashPt = | FlashPt =
| Autoignition = | AutoignitionPt =
}} }}
}} }}

'''Tanespimycin''' ('''17-''N''-allylamino-17-demethoxygeldanamycin''', '''17-AAG''') is a derivative of the antibiotic ] that is being studied in the treatment of ], specifically in younger patients with certain types of ] or solid ], especially ] ].

It works by ] ], which is expressed in those tumors.<ref>{{cite journal | vauthors = Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG | title = Tanespimycin as antitumor therapy | journal = Clinical Lymphoma, Myeloma & Leukemia | volume = 11 | issue = 1 | pages = 17–22 | date = February 2011 | pmid = 21454186 | doi = 10.3816/CLML.2011.n.002 }}</ref>

It belongs to the family of ] called ]s.

==Clinical trials==

] conducted Phase 1<ref>{{ClinicalTrialsGov|NCT00093821|Phase 1 trial: 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors}}</ref><ref>{{ClinicalTrialsGov|NCT00079404|Phase 1 trial: 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia}}</ref> and Phase 2 ]s. However, in 2010 the company halted ] of tanespimycin, during late-stage clinical trials as a potential treatment for multiple myeloma. While no definitive explanation was given, it has been suggested that Bristol-Myers Squibb halted development over concerns of the financial feasibility of tanespimycin development given the 2014 expiry of the patent on this compound, and the relative expense of manufacture.<ref name="available">{{Cite web | url=http://www.myelomabeacon.com/news/2010/07/22/tanespimycin-development-halted/ | archive-url = https://web.archive.org/web/20101228122346/http://www.myelomabeacon.com/news/2010/07/22/tanespimycin-development-halted/ | archive-date = 28 December 2010 |title = Bristol-Myers Squibb Halts Development of Tanespimycin | date = 22 July 2010 | work = The Myeloma Beacon }}</ref>

== References ==
{{Reflist}}

== External links ==
*
*

]
]
]
]
]
]
]
]